Anne Wojcicki, CEO of 23andMe, spent a decade in healthcare and biotechnology before launching the DNA testing and analysis company in 2006. Her goal was twofold: to help individuals learn more about their own genetics, enabling them to pursue more personalized medical care, and to create a database of genetic information for commercial and academic researchers to promote broader improvements to the healthcare system. She speaks with HBR's Editor-in-Chief Adi Ignatius about tackling challenges in an emerging industry.
Podden och tillhörande omslagsbild på den här sidan tillhör Harvard Business Review. Innehållet i podden är skapat av Harvard Business Review och inte av, eller tillsammans med, Poddtoppen.
